Metal-substituted protein MRI contrast agents engineered for enhanced relaxivity and ligand sensitivity.

S 1 Metal - substituted protein MRI contrast agents engineered for enhanced relaxivity and ligand sensitivity

Design of Novel Protein-based MRI Contrast Agernets with High Relaxivity and Stability for Biomedical Imaging

Magnetic resonance imaging (MRI) is the leading imaging technique for disease diagnostics. MRI contrast agents facilitate MRI technique to obtain tissue-specific image with improved sensitivity and signal-to-noise ratio. However, the applications of current MRI contrast agents are hampered by their uncontrolled blood circulation time, low relaxivity, and low specificity. To address such need, I...

A New Potential Contrast Agent for Magnetic Resonance Imaging: Iron Oxide-4A Nanocomposite

Background: Magnetic resonance imaging (MRI) contrast agents have an important role to differentiate healthy and diseased tissues. Access and design new contrast agents for the optimal use of MRI are necessary. This study aims to evaluate iron oxide–4A nanocomposite ability to act as a magnetic resonance imaging contrast agent.Materials and Methods: Iron oxide–4A nanocomposite (F4A) was syn...

Europium-engineered iron oxide nanocubes with high T1 and T2 contrast abilities for MRI in living subjects.

Magnetic resonance imaging (MRI) contrast agents with both positive (T1) and negative (T2) contrast abilities are needed in clinical diagnosis for fault-free accurate detection of lesions. We report a facile synthesis of europium-engineered iron oxide (EuIO) nanocubes as T1 and T2 contrast agents for MRI in living subjects. The Eu(iii) oxide-embedded iron oxide nanoparticles significantly incre...

Optimization of Expression and Purification Methods for the Study of Protein-Based Magnetic Resonance Imaging Contrast Agents

Magnetic Resonance Imaging instruments rely on a contrast agent to provide high-resolution images of tissues in vivo. However, current clinical contrast agents are hindered by low relaxivity and fast correlation time, necessitating high injection dosages. These concerns, among others, have driven the development of a class of protein-based contrast agents (ProCAs), by design of lanthanide bindi...